2025 Approvals
ROMVIMZA(vimseltinib): A New Treatment for Tenosynovial Giant Cell Tumor Approved by the FDA on February 14 2025
What is it prescribed for? ROMVIMZA is prescribed for adults with symptomatic tenosynovial giant cell tumor (TGCT) also known as Giant Cell Tumor of the Tendon Sheath, where surgery is likely to cause worsening functional problems or serious harm . What is the name of the drug and what does it